FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. TSRI 609.1	SERIAL NO. 09/581,044
	APPLICANT Lee, et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE 06/ 08/ 2000	GROUP 1653

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	1	5,157,041	10/ 20/ 1992	Handa, et al.			
	2	5,354,866	10/ 11/ 1994	Kempf, et al.			
	3	5,502,060	3/ 26/ 1996	Thompson, et al.			
	4	5,541,321	7/ 30/ 1996	Baker, et al.			
	5	5,567,823	10/ 22/ 1996	Tien, et al.			
	6	5,733,906	3/ 31/ 1998	Jungheim, et al.			

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
	7	WO 93/23361	11/ 25/ 1993				
	8	EP 0 751 145 A2	1/ 2/ 1997				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

JSR	9	Huff, "HIV Protease: A Novel Chemotherapeutic Target for AIDS", J. Med. Chem. 34: 2305-2314 (1991)
	10	Dreyer, et al. "A Symmetric Inhibitor Binds HIV-1 Protease Asymmetrically", Biochemistry 32: 937-947 (1993)
JSR	11	Otto, et al., "*In vitro* isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 Symmetrical inhibitors of HIV type 1 protease", Proc. Natl. Acad. Sci. USA 90: 7543-7547 (1993)
JSR	12	Wlodawer, et al., "Structure-Based Inhibitors of HIV-1 Protease", Annu. Rev. Biochem. 62: 543-585 (1993)
JSR	13	Condra, et al., "*In vivo* emergence of HIV-1 variants resistant to multiple protease inhibitors", Nature 374: 569-571 (1995)
JSR	14	Wlodawer, et al., "Structure of an inhibitor complex of the proteinase from feline immunodeficiency virus", Nature Struct. Biol. 2: 480-488 (1995)
JSR	15	Erickson, "The not-so-great escape", Nature Struct. Biol. 2: 523-529 (1995)
JSR	16	Slee, et al., "Selectivity in the Inhibition of HIV and FIV Protease: Inhibitory and Mechanistic Studies of Pyrrolidine-Containing α-Keto Amide and Hydroxyethylamine Core Structures", J. Am. Chem. Soc. 117: 11867-11878 (1995)
JSR	17	Budt, et al., "HIV Protease Inhibitor HOE/BAY 793, Structure-Activity Relationships in a Series of C_2-Symmetric Diols", Bioorg. Med. Chem. 3: 559-571 (1995)
JSR	18	Gulnik, et al., "Kinetic Characterization and Cross-Resistance Patterns of HIV-1 Protease Mutants Selected under Drug Pressure", Biochemistry 34: 9282-9287 (1995)
JSR	19	Erickson, et al., "Structural Mechanisms of HIV Drug Resistance", Annu. Rev. Pharmacol. Toxicol. 36: 545-571 (1996)

EXAMINER	DATE CONSIDERED
Jeffrey E. Russel	October 11, 2001

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. TSRI 609.1	SERIAL NO. 09/581,044
	APPLICANT Lee, et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE 6/ 8/ 2000	GROUP 1653

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

JRL	20 ✓	De Lucca, et al., "Cyclic HIV Protease Inhibitors capable of displacing the active site structural waster molecule" Drug Discovery Today 2: 6-18 (1997)
JRL	21 ✓	Wilson, et al., "Escape Mutants of HIV-1 Proteinase: Enzymic Efficiency and Susceptibility to Inhibition", Biochim. Biophys. Acta 1339: 113-115 (1997)
JRL	22 ✓	Vacca, et al., "Clinically Effective HIV-1 Protease Inhibitors", Drug Discovery Today 2: 261-272 (1997)
JRL	23 ✓	Wong, et al., "Recovery of Replication-Competent HIV Despite Prolonged Suppression of Plasma Viremia", Science 278: 1291-1295 (1997)
JRL	24 ✓	Finzi, et al., "Identification of a Reservoir of HIV-1 in Patients on Highly Active Antiretroviral Therapy", Science 278: 1295-1300 (1997)
JRL	25 ✓	Lee, et al., "Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: Development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV *in vitro* and *ex vivo*", Proc. Natl. Acad. Sci. USA 95: 939-944 (1998)

EXAMINER	DATE CONSIDERED
Jeffrey E. Russel	October 11.2001

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.